Gimv Invests in Camel-IDS

Our member Gimv participated in the biggest Series-A round in Belgium: the biotech company Camel-IDS raised a whopping 37 million EUR in European funding. 

Camel-IDS develops radio-immunotherapeutic drugs against cancer on the basis of antibodies from camels.

Read more (FR) & (NL)

Leave a Reply

Your email address will not be published. Required fields are marked *